Celularity Inc. (CELU)
NASDAQ: CELU · Real-Time Price · USD
1.520
-0.070 (-4.40%)
At close: Nov 14, 2025, 4:00 PM EST
1.550
+0.030 (1.97%)
After-hours: Nov 14, 2025, 4:10 PM EST
Celularity Revenue
Celularity had revenue of $5.74M in the quarter ending June 30, 2025, a decrease of -52.64%. This brings the company's revenue in the last twelve months to $44.59M, up 4.45% year-over-year. In the year 2024, Celularity had annual revenue of $54.22M with 138.11% growth.
Revenue (ttm)
$44.59M
Revenue Growth
+4.45%
P/S Ratio
0.80
Revenue / Employee
$362,520
Employees
123
Market Cap
41.37M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 54.22M | 31.45M | 138.11% |
| Dec 31, 2023 | 22.77M | 4.80M | 26.68% |
| Dec 31, 2022 | 17.98M | -3.36M | -15.75% |
| Dec 31, 2021 | 21.34M | 7.06M | 49.43% |
| Dec 31, 2020 | 14.28M | -6.87M | -32.48% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
CELU News
- 15 days ago - Celularity and DefEYE, Inc. Partner to Advance Growth of Regenerative Therapies in Eye Care - GlobeNewsWire
- 4 weeks ago - Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral Artery Disease - GlobeNewsWire
- 2 months ago - Celularity Announces Filing of Form 10-Q Quarterly Reports for the First Quarter and the Second Quarter 2025, Confirmation of Nasdaq Listing Rule 5250(c)(1) Compliance - GlobeNewsWire
- 3 months ago - Celularity Receives Nasdaq Notice Regarding Form 10-Q - GlobeNewsWire
- 3 months ago - Celularity Completes Major Balance Sheet Restructuring, Retires All $41.6 Million in Senior Secured Debt - GlobeNewsWire
- 4 months ago - Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law - GlobeNewsWire
- 4 months ago - Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies - GlobeNewsWire
- 5 months ago - Celularity Announces Chief Financial Officer Transition - GlobeNewsWire